Neuracle NEO-ONE SCI获首张处方:世界首个侵入式BCI产品进入临床

Neuracle Writes First Brain-Computer Interface Prescription: World First Invasive BCI Product Enters Clinical Use

精选理由

中国公司Neuracle的侵入式BCI产品已经真正开出处方、进医保了,比Neuralink更快走完商业闭环,看看他们怎么做到的。

AI 摘要

Neuracle NEO-ONE SCI在上海华山医院开出首张处方,成为全球首个完成从审批到手术到保险覆盖全商业周期的侵入式脑机接口产品。该设备此前已获得中国NMPA批准,用于帮助瘫痪患者恢复运动功能。此次处方标志着侵入式BCI正式从研发走向临床大规模应用。

原文 · pandaily

Neuracle Writes First Brain-Computer Interface Prescription: World First Invasive BCI Product Enters Clinical Use

Neuracle NEO-ONE SCI receives first prescription at Shanghai Huashan Hospital, completing the world first full commercial cycle of an invasive BCI device from approval to surgery to insurance coverage.